Cargando…

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension

The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Momoi, Mizuki, Hiraide, Takahiro, Shinya, Yoshiki, Momota, Hiromi, Fukui, Shogo, Kawakami, Michiyuki, Fukuda, Keiichi, Kataoka, Masaharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819132/ https://www.ncbi.nlm.nih.gov/pubmed/35145843 http://dx.doi.org/10.1016/j.rmcr.2022.101592

Ejemplares similares

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

RNF213-Associated Vascular Disease: A Concept Unifying Various Vasculopathies
por: Hiraide, Takahiro, et al.
Publicado: (2022)

TET2 Variants in Japanese Patients With Pulmonary Arterial Hypertension
por: Hiraide, Takahiro, et al.
Publicado: (2021)

Long-term Follow-up of Qing-Dai–Induced Pulmonary Arterial Hypertension: A Case Series
por: Matsushima, Takahide, et al.
Publicado: (2023)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
por: Shinya, Yoshiki, et al.
Publicado: (2021)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
por: Khan, Akram, et al.
Publicado: (2023)

Factors related to instrumental activities of daily living in persons with chronic thromboembolic pulmonary hypertension
por: Iwasawa, Tatsuya, et al.
Publicado: (2021)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
por: Hoch, Matthias, et al.
Publicado: (2014)

Exercise prescription using an insertable cardiac monitor in a patient with catecholaminergic polymorphic ventricular tachycardia
por: Momoi, Mizuki, et al.
Publicado: (2021)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022)

Genetic Testing Enables the Diagnosis of Familial Hypercholesterolemia Underdiagnosed by Clinical Criteria: Analysis of Japanese Early-Onset Coronary Artery Disease Patients
por: Miyama, Hiroshi, et al.
Publicado: (2023)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Regional Right Ventricular Abnormalities Implicate Distinct Pathophysiological Conditions in Patients With Chronic Thromboembolic Pulmonary Hypertension
por: Moriyama, Hidenori, et al.
Publicado: (2020)

The complement C3-complement factor D-C3a receptor signalling axis regulates cardiac remodelling in right ventricular failure
por: Ito, Shogo, et al.
Publicado: (2022)

Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs
por: Louis, Lam, et al.
Publicado: (2012)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Preoperative Instrumental Activities of Daily Living Predicts Survival After Transcatheter Aortic Valve Implantation
por: Fukui, Shogo, et al.
Publicado: (2020)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

Qualitative and Quantitative Effects of Fatty Acids Involved in Heart Diseases
por: Moriyama, Hidenori, et al.
Publicado: (2022)

Exercise tolerance and quality of life in hemodynamically partially improved patients with chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty
por: Miura, Kotaro, et al.
Publicado: (2021)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis
por: Tada, Satoru, et al.
Publicado: (2019)

The Prostacyclin Analog Beraprost Sodium Ameliorates Characteristics of Metabolic Syndrome in Obese Zucker (Fatty) Rats
por: Sato, Nahoko, et al.
Publicado: (2010)

Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis
por: Zhang, Huijun, et al.
Publicado: (2016)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
por: Sargent, Therese, et al.
Publicado: (2020)

Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study
por: Kawakami, Takashi, et al.
Publicado: (2020)

Antiproliferative effect of selexipag active metabolite MRE‐269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension
por: Kuramoto, Kazuya, et al.
Publicado: (2023)

PROSTACYCLIN IN HEALTH AND DISEASE
Publicado: (1983)

Prostacyclin: An Inflammatory Paradox
por: Stitham, Jeremiah, et al.
Publicado: (2011)

Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors
por: Blitek, Agnieszka, et al.
Publicado: (2022)

Pharmacokinetics of a single inhalation of hydrogen gas in pigs
por: Sano, Motoaki, et al.
Publicado: (2020)

Synthetic Prostacyclin Agonist Attenuates Pressure-Overloaded Cardiac Fibrosis by Inhibiting FMT
por: Masada, Kenta, et al.
Publicado: (2020)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0pdo5rvdcvkjhduq5158hp3gnr